✦ LIBER ✦

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

✍ Scribed by Sandhya Girish; Manish Gupta; Bei Wang; Dan Lu; Ian E. Krop; Charles L. Vogel; Howard A. Burris III; Patricia M. LoRusso; Joo-Hee Yi; Ola Saad; Barbara Tong; Yu-Waye Chu; Scott Holden; Amita Joshi

Book ID: 113028050
Publisher: Springer
Year: 2012
Tongue: English
Weight: 520 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-011-1817-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ado-trastuzumab emtansine (T-DM1): a nov

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer

✍ Baron, J. M.; Boster, B. L.; Barnett, C. M. 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 165 KB

Phase I Study of Trastuzumab-DM1, an HER

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

✍ Krop, I. E.; Beeram, M.; Modi, S.; Jones, S. F.; Holden, S. N.; Yu, W.; Girish, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 153 KB

Indirect Comparison Analysis to Evaluate

Indirect Comparison Analysis to Evaluate the Clinical Effectiveness of Trastuzumab Emtansine (T-DM1) Versus Other Treatments for HER2-Positive Metastatic Breast Cancer (MBC)

✍ Benito Garcia, E.; Hersberger, V.; Takyar, S.; Moser, A. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Phase II Study of the Antibody Drug Conj

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy

✍ Burris, H. A.; Rugo, H. S.; Vukelja, S. J.; Vogel, C. L.; Borson, R. A.; Limenta 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 176 KB

A population pharmacokinetic/pharmacodyn

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

✍ Bender, Brendan C.; Schaedeli-Stark, Franziska; Koch, Reinhold; Joshi, Amita; Ch 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 755 KB

5020 Pharmacokinetics (PK), safety, and

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

✍ H. Burris III; S. Vukelja; I. Krop; S. Modi; B. Klencke; S. Girish; M.X. Sliwkow 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB